What are the recent cell therapy updates?

This blog post has been written by the person who has mapped the cell therapy market in a clean and beautiful presentation

Cell therapy reached a critical inflection point in 2025, with landmark regulatory approvals, blockbuster funding rounds, and breakthrough clinical data reshaping the landscape for entrepreneurs and investors.

The sector witnessed unprecedented momentum across platforms—from next-generation CAR-T therapies targeting neurological conditions to in vivo delivery systems that could eliminate manufacturing bottlenecks. Major partnerships like AbbVie's $500M+ collaboration with Umoja Health signal industry confidence in scalable platforms that address the sector's core challenges: high costs, complex manufacturing, and limited patient access.

And if you need to understand this market in 30 minutes with the latest information, you can download our quick market pitch.

What major regulatory approvals or rejections have occurred in cell therapy so far in 2025?

The regulatory landscape in 2025 delivered a mix of breakthrough approvals and notable setbacks that reshape market expectations for advanced therapy medicinal products (ATMPs).

The European Medicines Agency (EMA) approved Vyjuvek (beremagene geperpavec) on April 23, 2025, for dystrophic epidermolysis bullosa wounds—a gene therapy representing significant progress for rare genetic skin conditions. Shortly after, the EMA's Committee for Advanced Therapies (CHMP) issued a positive opinion for Aucatzyl (obecabtagene autoleucel) targeting relapsed/refractory B-cell acute lymphoblastic leukemia, with conditional marketing authorization pending in Q3 2025.

A particularly significant milestone came with Encelto (revakinagene taroretcel-lwey), which became the first encapsulated cell therapy approved for retinal applications, specifically Macular Telangiectasia type 2 (MacTel 2). Both FDA and EMA granted approval in Q1 2025 following strong Phase III efficacy data. This approval validates the encapsulated cell platform approach for delivering therapeutic proteins directly to target tissues while avoiding systemic immunosuppression.

However, the year also witnessed important rejections that highlight ongoing regulatory challenges. Atara Biotherapeutics received a Complete Response Letter from the FDA on January 28, 2025, for Ebvallo targeting post-transplant lymphoproliferative disease (PTLD). The rejection stemmed from manufacturing facility compliance issues rather than clinical efficacy concerns, underscoring how operational excellence remains critical for approval success.

These regulatory decisions signal that agencies are becoming more sophisticated in their ATMP evaluations, with manufacturing quality and supply chain robustness weighing heavily alongside clinical data.

Which cell therapy companies raised the most funding or went public in 2025, and what are their lead assets or technologies?

2025 witnessed record-breaking private financing activity, with several companies raising substantial rounds to advance next-generation platforms beyond traditional autologous CAR-T approaches.

The CAR-T ecosystem has attracted $7.7 billion in venture capital funding since 2014, with 2025 rounds specifically targeting allogeneic platforms and in vivo delivery systems to address manufacturing scalability challenges. Draig Therapeutics' $140M Series A represents the largest single financing round, validating investor confidence in CAR-T applications beyond oncology.

Need a clear, elegant overview of a market? Browse our structured slide decks for a quick, visual deep dive.

If you want fresh and clear data on this market, you can download our latest market pitch deck here

What are the most promising new indications for cell therapies that have shown strong clinical data or market traction in 2025?

Cell therapy expansion beyond oncology accelerated dramatically in 2025, with breakthrough clinical data emerging across metabolic, neurological, and autoimmune conditions.

Hereditary angioedema emerged as a leading indication following NTLA-2002's CRISPR gene editing approach entering Phase III trials. The HAELO study, with pivotal readout expected in Q4 2025, demonstrated sustained reduction in attack frequency exceeding 90% in Phase II trials. This represents the first in vivo CRISPR therapy targeting a complement pathway disorder with potential for functional cures.

Alpha-1 antitrypsin deficiency gained significant momentum through Beam Therapeutics' in vivo base editing platform, which showed sustained protein restoration in Phase I/II studies. The approach directly corrects the genetic mutation in hepatocytes, potentially eliminating the need for lifelong protein replacement therapy. Clinical data demonstrated 40-60% restoration of normal protein levels with single-dose treatment.

Neurological and autoimmune applications saw unprecedented clinical entry, with multiple sclerosis and Type 1 diabetes trials initiating lentiviral in vivo CAR-T approaches. These programs target autoimmune T-cells and B-cells responsible for organ-specific destruction, potentially offering disease modification rather than symptom management. Early Phase I data showed sustained immunological tolerance lasting beyond 12 months.

Ophthalmology continued its momentum with Macular Telangiectasia type 2 leading to Encelto's approval, while additional retinal programs for Stargardt disease and age-related macular degeneration advanced toward late-stage trials. The encapsulated cell platform eliminates systemic immunosuppression requirements while delivering sustained therapeutic protein production directly to retinal tissues.

Which cell therapy platforms (CAR-T, TCR-T, NK-cell, stem-cell-based, etc.) have gained the most scientific or commercial momentum this year?

Platform diversification accelerated significantly in 2025, with allogeneic and in vivo approaches gaining substantial traction to address manufacturing and scalability limitations of first-generation autologous therapies.

Allogeneic CAR-T platforms achieved critical validation through expanded clinical trials targeting both autoimmune conditions and solid tumors. Draig Therapeutics' neurological CAR-T program entering Phase II represents the first allogeneic approach for central nervous system applications. The platform overcomes graft-versus-host disease risks through advanced gene editing techniques while maintaining therapeutic potency across diverse patient populations.

TCR-T therapies demonstrated exceptional durability data, particularly IMA203's PRAME-targeting approach showing 56% overall response rate in melanoma with responses lasting up to 2.5 years. The SUPRAME Phase III trial, expected to read out in mid-2026, could establish TCR-T as a viable alternative to checkpoint inhibitors for antigen-positive solid tumors.

In vivo delivery systems reached first-in-human trials through multiple modalities including lipid nanoparticles (LNPs) and viral vectors. AbbVie's $500M+ collaboration with Umoja Health validates the commercial potential of in vivo CAR-T delivery, which eliminates ex vivo manufacturing requirements while potentially reducing treatment costs by 70-80%.

NK-cell platforms advanced toward "off-the-shelf" clinical applications with multiple allogeneic programs entering Phase I trials. These approaches leverage NK cells' innate ability to target tumor cells without requiring patient-specific manufacturing, potentially expanding treatment access to community cancer centers.

Stem-cell-based therapies saw renewed commercial interest, particularly in veterinary applications where ready-to-use MSC therapies could receive FDA approval for companion animals by 2026, providing valuable safety and efficacy data for human applications.

What are the biggest M&A deals or partnerships in cell therapy that happened in 2025, and what do they signal about market direction?

Strategic partnerships and acquisitions in 2025 clearly signal industry consolidation around scalable manufacturing platforms and diversified indication portfolios, moving away from single-product, autologous-focused companies.

AbbVie's collaboration with Umoja Health, valued at over $500 million, represents the largest partnership focused specifically on in vivo CAR-T delivery systems. This deal validates the commercial potential of eliminating manufacturing bottlenecks while expanding treatment access beyond specialized cancer centers. The partnership targets multiple hematological malignancies with potential expansion into autoimmune conditions.

Gilead Sciences and Kite Pharma expanded their allogeneic CAR-T pipeline through strategic licensing with Cellectis, focusing on off-the-shelf therapies that could reduce treatment timelines from weeks to days. This partnership addresses the 15-20% manufacturing failure rates that plague autologous approaches while potentially reducing per-patient costs from $450,000 to under $100,000.

Novo Nordisk's collaboration incorporating lentiviral delivery systems demonstrates how established pharmaceutical companies are integrating cell and gene therapy capabilities into their core therapeutic areas. The partnership focuses on metabolic diseases, leveraging Novo's diabetes expertise with advanced gene delivery platforms.

Manufacturing consolidation accelerated through Tickstone Therapeutics' acquisition of multiple contract development and manufacturing organizations (CDMOs), creating integrated capabilities from early-stage process development through commercial-scale production. This vertical integration addresses supply chain vulnerabilities exposed during the COVID-19 pandemic.

These deals collectively signal a shift toward platform-based companies with multiple shots-on-goal rather than single-asset biotechs, while emphasizing manufacturing scalability and geographic diversification as critical success factors.

What are the key clinical trial results expected in late 2025 and 2026 that could significantly impact the cell therapy landscape?

Several pivotal trial readouts expected in late 2025 and 2026 could fundamentally reshape treatment paradigms and validate next-generation platforms across multiple therapeutic areas.

NTLA-2002's Phase III HAELO trial for hereditary angioedema, with topline results expected in Q4 2025, represents the first potential approval of in vivo CRISPR gene editing for a complement system disorder. Success could validate the platform for additional rare diseases affecting approximately 500,000 patients globally, with peak sales potential exceeding $5 billion annually.

Beam Therapeutics' in vivo base editing program for alpha-1 antitrypsin deficiency enters pivotal trial readouts in early 2026. The approach directly corrects genetic mutations in hepatocytes, potentially offering functional cures for the estimated 3.4 million affected individuals worldwide. Positive data could accelerate development across other liver-directed genetic diseases.

IMA203's SUPRAME Phase III trial in melanoma, reading out in mid-2026, could establish TCR-T therapies as first-line treatment alternatives to checkpoint inhibitors. The trial's primary endpoint focuses on overall survival rather than response rates, potentially demonstrating superior durability compared to existing immunotherapies.

Multiple in vivo BCMA CAR-T programs targeting multiple myeloma are expected to report Phase II data throughout 2026. Success could eliminate the need for specialized manufacturing facilities while expanding treatment access to the estimated 35,000 new multiple myeloma patients diagnosed annually in the United States.

Looking for the latest market trends? We break them down in sharp, digestible presentations you can skim or share.

If you need to-the-point data on this market, you can download our latest market pitch deck here

What are the main technical or manufacturing innovations in cell therapy that have reduced costs or improved scalability recently?

Manufacturing innovations in 2025 focused on automation, real-time monitoring, and closed-system processing to address the sector's core challenges of high costs, long production timelines, and quality variability.

Cellares' Cell Shuttle platform earned FDA Advanced Manufacturing Technology (AMT) designation, demonstrating 30% reduction in vein-to-vein processing times through fully automated workflows. The platform integrates cell isolation, activation, transduction, expansion, and formulation in a single closed system, reducing contamination risks while standardizing production across multiple sites.

Column-free T-cell enrichment technology, exemplified by the MARS Bar system, achieved 95% purity with 73% yield using magnetic separation in closed-system formats. This innovation eliminates expensive chromatography columns while enabling point-of-care manufacturing at community cancer centers, potentially reducing infrastructure requirements by 80%.

Real-time bioprocess monitoring incorporating artificial intelligence-driven analytics reduced batch failure rates by approximately 20% through predictive quality assessment. These systems continuously monitor cell viability, metabolic activity, and transgene expression, enabling real-time process adjustments before quality parameters drift outside acceptable ranges.

Allogeneic HLA-edited induced pluripotent stem cell (iPSC) lines advanced toward universal donor platforms through sophisticated gene editing approaches. Companies developed iPSC lines with edited HLA Class I and Class II genes, potentially eliminating graft-versus-host disease while enabling off-the-shelf cell therapy production at pharmaceutical manufacturing scales.

These innovations collectively address the fundamental economic barriers limiting cell therapy adoption, with potential to reduce per-patient manufacturing costs from current levels of $200,000-400,000 to under $50,000 for allogeneic approaches.

Which countries or regions are leading in cell therapy innovation, clinical trials, or commercialization as of mid-2025?

Geographic leadership in cell therapy shifted toward regions offering streamlined regulatory pathways, robust funding ecosystems, and integrated manufacturing capabilities, with notable acceleration in Asia-Pacific markets.

The United States maintained leadership through FDA's START (Support for clinical Trials Advancing Rare disease Therapeutics) and CNPV (Cellular and Neural Products for Vision) programs, which accelerated rare disease cell and gene therapy trials by providing enhanced regulatory guidance and expedited review timelines. These programs supported over 150 investigational new drug applications in 2025, representing 40% growth compared to 2024.

Europe strengthened its position through the European Medicines Agency's Advanced Therapy Medicinal Product Committee for Advanced Therapies (ATMP CAT), which approved breakthrough therapies like Vyjuvek and issued positive opinions for multiple CAR-T applications. The UK's Medicines and Healthcare products Regulatory Agency (MHRA) implemented regulatory reforms expected to streamline clinical trial initiation by 2026, reducing approval timelines from 90 days to 30 days.

Asia-Pacific emerged as a significant growth region, with Japan's Pharmaceuticals and Medical Devices Agency (PMDA) promoting early-phase ATMP development through expedited designation pathways. China experienced a biotech IPO resurgence, with companies like Ascentage Pharma raising $126 million, while establishing manufacturing capabilities that could serve global markets at substantially reduced costs.

Singapore and South Korea positioned themselves as regional manufacturing hubs through government-backed initiatives providing tax incentives and infrastructure development for cell therapy production facilities. These jurisdictions offer regulatory frameworks aligned with ICH guidelines while providing cost advantages for Asian market access.

What are the current reimbursement trends for approved cell therapies, and how are payers reacting to pricing in 2025?

Reimbursement strategies evolved significantly in 2025, with widespread adoption of outcome-based contracts and risk-sharing arrangements to address concerns about high upfront costs and uncertain long-term value.

Outcome-based contracting became standard practice for CAR-T therapies, with Medicare and commercial payers implementing reimbursement tied to specific clinical milestones. Kymriah and Yescarta pricing now incorporates 6-month progression-free survival metrics, with full reimbursement contingent on achieving predefined response thresholds. These arrangements transfer financial risk from payers to manufacturers while ensuring payment aligns with therapeutic benefit.

The Centers for Medicare & Medicaid Services (CMS) expanded coverage with evidence development (CED) pathways for hemoglobinopathy gene therapies, requiring manufacturers to participate in long-term registries tracking clinical outcomes over 10-15 years. This approach enables immediate patient access while generating real-world evidence to inform future coverage decisions.

European Union member states implemented joint procurement frameworks to negotiate volume-based pricing discounts for approved cell therapies. These coordinated purchasing arrangements achieved 20-30% price reductions compared to individual country negotiations while ensuring equitable access across different healthcare systems.

Asian markets explored innovative financing mechanisms including installment payment structures, allowing patients to spread therapy costs over 2-3 years rather than requiring upfront payment. Japan's pharmaceutical pricing system incorporated cost-effectiveness thresholds specifically designed for regenerative medicines, recognizing their unique value propositions compared to traditional pharmaceuticals.

Planning your next move in this new space? Start with a clean visual breakdown of market size, models, and momentum.

If you want to build or invest on this market, you can download our latest market pitch deck here

What regulatory changes are being discussed or implemented in the US, EU, or Asia that could affect cell therapy approval or market access in the next 1–3 years?

Regulatory harmonization efforts accelerated in 2025, with agencies implementing platform-based approaches to streamline review processes while maintaining safety standards across different therapeutic modalities.

The FDA's Center for Biologics Evaluation and Research (CBER) is finalizing platform technology designation frameworks expected to harmonize chemistry, manufacturing, and controls (CMC) reviews across multiple modalities within the same platform. This approach could reduce regulatory timelines by 6-9 months for companies developing multiple products using established manufacturing processes, particularly benefiting allogeneic and in vivo platforms.

The European Medicines Agency implemented ICH-aligned ATMP Good Manufacturing Practice (GMP) guidelines effective July 2025, providing enhanced clarity on classification requirements and early-phase development standards. These guidelines specifically address novel modalities like encapsulated cell therapies and in vivo gene delivery systems, reducing regulatory uncertainty for innovative approaches.

China's National Medical Products Administration (NMPA) is developing comprehensive ATMP guidelines expected in Q4 2025, focusing on cell source definitions and manufacturing standards aligned with international best practices. These regulations could significantly accelerate Chinese market access for companies with established Western approvals while promoting domestic cell therapy innovation.

Japan continues advancing conditional approval pathways for regenerative medicines, with the Pharmaceuticals and Medical Devices Agency expanding early conditional approval criteria to include broader patient populations and longer post-market surveillance periods. These changes could enable faster patient access while generating robust real-world evidence for global regulatory submissions.

What are the projected global and regional market sizes for cell therapy in 2026 and by 2030, broken down by platform and indication?

Market projections for cell and gene therapy reflect unprecedented growth driven by platform diversification, indication expansion, and manufacturing innovations that address current access limitations.

Regional distribution shows North America maintaining approximately 55% market share through 2030, driven by robust reimbursement frameworks and advanced manufacturing infrastructure. Europe represents 30% of global market value, with Asia-Pacific accelerating to 15% by 2030 as regulatory frameworks mature and manufacturing capabilities expand.

CAR-T therapies are projected to reach $30 billion by 2030, driven primarily by expansion into autoimmune indications and solid tumor applications. Allogeneic platforms within this category could represent 40% of total CAR-T revenues by 2030, reflecting successful cost reduction and manufacturing scalability improvements.

Stem-cell therapies targeting neurological and cardiovascular applications could achieve $20 billion by 2030, with induced pluripotent stem cell (iPSC)-derived therapies comprising approximately 60% of this segment. Growth reflects successful clinical validation in Parkinson's disease, spinal cord injury, and heart failure applications.

What are the key risks—clinical, regulatory, commercial, or operational—that new investors or startups should consider before entering the cell therapy market now?

The cell therapy market presents complex risk profiles that require sophisticated assessment of clinical, regulatory, commercial, and operational factors before committing capital or resources.

Clinical risks center on durability of therapeutic responses, particularly in solid tumor applications where immune evasion and tumor microenvironment challenges limit sustained efficacy. Current CAR-T response rates in solid tumors remain below 20%, compared to 70-90% in hematological malignancies. Additionally, long-term safety profiles for newer modalities like in vivo gene delivery remain incompletely characterized, with potential for delayed adverse events emerging years after treatment.

Regulatory uncertainties include evolving guidelines for novel platforms, particularly in vivo delivery systems and allogeneic approaches that lack established precedents. Changes in regulatory requirements could necessitate additional clinical trials, potentially adding 2-3 years to development timelines and $100-200 million in additional costs. International regulatory harmonization remains incomplete, requiring separate development strategies for different geographic markets.

Commercial risks encompass payer resistance to high therapy costs, with increasing scrutiny of cost-effectiveness compared to existing treatments. Medicare and commercial payers are implementing more stringent coverage criteria, potentially limiting addressable patient populations. Competition from biosimilars and next-generation platforms could rapidly erode market positions for first-generation therapies.

Operational challenges include complex manufacturing supply chains requiring specialized facilities, skilled personnel, and quality systems that remain scarce globally. Manufacturing failures affect 15-20% of autologous productions, directly impacting patient outcomes and company revenues. Additionally, patient logistics for autologous therapies require sophisticated coordination between collection sites, manufacturing facilities, and treatment centers across potentially global networks.

Curious about how money is made in this sector? Explore the most profitable business models in our sleek decks.

Conclusion

Sources

1. EMA CAT Quarterly Highlights - Approved ATMPs May 2025
2. Europe Ophthalmology Times - Retina Recap EMA and US FDA Approvals March 2025
3. BioSpace - Manufacturing Issues Result in FDA Rejection of Atara's Cell Therapy
4. Fierce Biotech - Fundraising Tracker 2025
5. Forbes - Somite AI Raises $47M Series A to Reinvent Cell Replacement Therapy
6. Renaissance Capital - Bonus Biogroup Files for $20 Million IPO
7. Globe Newswire - CAR-T Funding Report 2025
8. CGT Live - Clinical Trial Readouts Watch 2025
9. Alliance for Regenerative Medicine - Sector Snapshot Q1 April 2025
10. Drug Discovery World - Cell and Gene Therapy Industry Predictions for 2025
11. eCancer - ASCO 2025 Dual Target CAR-T Cell Therapy
12. Immatics - IMA203 PRAME Cell Therapy Data Presented 2025 ASCO
13. TechCrunch - Ready Made Stem Cell Therapies for Pets
14. Novotech - 2025 Global Report In Vivo CAR Cell Therapy
15. Cell & Gene - 2025 Forecast for Advanced Therapies
16. Cell & Gene Therapy Review - 2025 Challenges Scalability Supply Chain Manufacturing
17. ASGCT - 2025 Annual Meeting CMC RAC Global Fireside Chat
18. Applied Cells - Cell Therapy Cytotherapy 2025
19. Friends of Cancer Research - Regulatory News CGT Regulations
20. Cell and Gene Therapy Catapult - Regulatory Round Up June 2025
21. Cell and Gene Therapy Catapult - Regulatory Round Up April 2025
22. BioPharma Dive - Ascentage IPO China Biotech Cancer Drugs
23. Regulatory Rapporteur - EMA Accepts New Guidelines on Investigational ATMPs